Can-fite Biopharma LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
AMEX
Can-Fite BioPharma Ltd. reported a net loss of $9.8 million for 2025, continuing its history of operating losses, while advancing its clinical pipeline and securing additional capital.
AMEX
Can-Fite BioPharma details its compensation policy for officers and reports financial results for the year ended December 31, 2024, in its latest SEC filing.
AMEX
Can-Fite BioPharma's 20-F filing highlights its clinical-stage biopharmaceutical focus, A3AR platform, and ongoing development of Piclidenoson and Namodenoson, while acknowledging continued operating losses and the need for additional capital.